NCT03439462已完成1 期
A Phase 1/2 Multi-center Investigation of ABI-009 (Nab-rapamycin) in Combination With FOLFOX and Bevacizumab as First-line Therapy in Patients With Advanced or Metastatic Colorectal Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 6
- 主要终点
- Dose-limiting-toxicities (DLTs) (Phase 1)
研究概览
简要总结
A phase 1/2 multi-center investigation of nab-sirolimus (also known as ABI-009, nab-rapamycin) in combination with mFOLFOX6 and Bevacizumab as first-line therapy in patients with metastatic colorectal cancer
详细描述
This study is a prospective phase 1/2, single arm, open-label, multi-institutional study to identify the RP2D and determine the efficacy and safety profile of nab-sirolimus administered as first-line therapy in combination with mFOLFOX6 and bevacizumab in patients with metastatic colorectal cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with histologically confirmed advanced or metastatic colorectal cancers for whom chemotherapy is indicated.
- •Patients must not have had prior chemotherapy for advanced or metastatic disease. Patients could have received adjuvant chemotherapy or adjuvant chemo-radiotherapy.
- •Patients must have at least 1 measurable site of disease according to RECIST v1.1 that has not been previously irradiated. If the patient has had previous radiation to the marker lesion(s), there must be radiological evidence of progression since the radiation.
- •Eligible patients, 18 years or older, with Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or
- •Patients must not have been previously treated with an mTOR inhibitor.
- •Adequate liver function:
- •Total bilirubin ≤1.5 x upper limit of normal (ULN) mg/dL
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x ULN (<5 x ULN if the patient has liver metastases).
- •Adequate renal function:
- •a. Serum creatinine ≤2 x ULN or creatinine clearance >50 cc/hr (Cockroft-Gault).
- •Adequate biological parameters:
- •Absolute neutrophil count (ANC) ≥1.5 × 109/L
- •Platelet count ≥100,000/mm3 (100 × 109/L)
- •Hemoglobin ≥9 g/dL.
- •Fasting serum triglyceride ≤300 mg/dL; fasting serum cholesterol ≤350 mg/dL.
- •INR and PTT <1.5 x ULN (anticoagulation is allowed if target INR <1.5 on a stable dose of warfarin or on a stable dose of LMW heparin for >2 weeks at time of enrollment).
- •Minimum of 4 weeks since any major surgery, completion of radiation, or completion of all prior systemic anticancer therapy, and ≥6 months since adjuvant FOLFOX therapy (adequately recovered from the acute toxicities of any prior therapy, including neuropathy should be grade ≤1).
- •Male or non-pregnant and non-breast feeding female:
- •Females of child-bearing potential must agree to use effective contraception without interruption from 28 days prior to starting IP throughout 3 months after last dose of IP and have a negative serum pregnancy test (β -hCG) result at screening and agree to ongoing pregnancy testing during the course of the study, and after the end of study treatment. A second form of birth control is required even if she has had a tubal ligation.
- •Male patients must practice abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study and throughout 3 months after last dose of IP. A second form of birth control is required even if he has undergone a successful vasectomy.
- •Life expectancy of >3 months, as determined by the investigator.
- •Ability to understand and sign informed consent.
- •Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures.
排除标准
- •History of severe and uncontrolled allergic reactions to bevacizumab
- •Prior treatment with FOLFOX or bevacizumab within the preceding 4 weeks
- •Patients currently receiving or have received anticancer therapies within 4 weeks of the start of study treatment (including chemotherapy, radiation therapy, antibody based therapy, etc.)
- •Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
- •Chronic treatment with systemic steroids or another immunosuppressive agent; topical or inhaled corticosteroids are allowed
- •Recent infection requiring systemic anti-infective treatment that was completed ≤14 days prior to enrollment (with the exception of uncomplicated urinary tract infection or upper respiratory tract infection).
- •Patients who have any severe and/or uncontrolled medical or psychiatric conditions or other conditions that could affect their participation including:
- •Known active uncontrolled or symptomatic central nervous system (CNS) metastases. A patient with controlled and asymptomatic CNS metastases may participate in this study. As such, the patient must have completed any prior treatment for CNS metastases ≥28 days (including radiotherapy and/or surgery) prior to start of treatment in this study and should not be receiving chronic corticosteroid therapy for the CNS metastases.
- •Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤6 months prior to first study treatment, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease
- •Pre-existing severely impaired lung function as defined as spirometry and DLCO that is 50% of the normal predicted value and/or O2 saturation that is 88% or less at rest on room air (Note: spirometry and PFTs not required to be performed unless clinically indicated).
- •Uncontrolled diabetes as defined by fasting serum glucose >1.5x ULN or by HbA1c >8% despite adequate therapy.
- •Any active (acute or chronic) or uncontrolled infection/ disorders.
- •Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy. Note, controlled non-melanoma skin cancers, carcinoma in situ of the cervix, resected incidental prostate cancer, or other adequately treated carcinoma-in-situ may be eligible, after documented discussion with the sponsor / medical monitor.
- •Known liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh class C).
- •Patients with history of interstitial lung disease and/or pneumonitis, or pulmonary hypertension.
- •A known history of HIV seropositivity.
- •Active Hepatitis B or Hepatitis C. Note: A detailed assessment of Hepatitis B/C medical history and risk factors must be done at screening for all patients. HBV DNA and HCV RNA PCR testing are required at screening for all patients with a positive medical history based on risk factors and/or confirmation of prior HBV/HCV infection.
- •Patients with an active bleeding diathesis or on oral anti-vitamin K medication (except low dose Coumadin).
- •Use of strong inhibitors and inducers of CYP3A4 within the 14 days prior to receiving the first dose of ABI-
- •Additionally, use of any known CYP3A4 substrates with narrow therapeutic window (such as fentanyl, alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, terfanide) within the 14 days prior to receiving the first dose of ABI-009.
研究组 & 干预措施
nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin)
Experimental
Single arm, open-label, multi-institutional study to identify the RP2D and determine the efficacy and safety profile of nab-sirolimus administered as first-line therapy in combination with mFOLFOX6 and bevacizumab in patients with metastatic CRC.
干预措施: nab-sirolimus (Drug)
结局指标
主要结局
Dose-limiting-toxicities (DLTs) (Phase 1)
时间窗: First 2 treatment cycles (2 months)
Dose-limiting-toxicities within the first 2 cycles of treatment with nab-sirolimus at various doses and schedule in combination with mFOLFOX6 and bevacizumab
Progression-free Survival at 6 Months (Phase 2) for All Patients, at the RP2D, as Well as Based on PTEN Status (Positive and Negative)
时间窗: 6 months
The PFS rate at 6 months was estimated using the Kaplan-Meier method for a) all efficacy evaluable patients, b) patients receiving treatment at the RP2D, and c) based on PTEN status (positive or negative). Progression-free survival was defined as the time from the first day of study drug administration to disease progression or death due to any cause. Response evaluation was performed per RECIST v1.1, with the criteria for progression is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.
次要结局
- Disease Control Rate (DCR) (Phase 2) for All Patients, at the RP2D, as Well as Based on PTEN Status (Positive and Negative)(Through study completion (up to 50 months))
- Median Progression-free Survival (Phase 2) for All Patients, at the RP2D, as Well as Based on PTEN Status (Positive and Negative)(Through study completion (up to 50 months))
- Overall Response Rate (Phase 2) for All Patients, at the RP2D, as Well as Based on PTEN Status (Positive and Negative)(Through study completion (up to 50 months))
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComaMalignant PEComaNCT02494570Aadi Bioscience, Inc.34
已完成
2 期
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR InhibitorsNeuroendocrine TumorsPulmonary Neuroendocrine TumorGastrointestinal Neuroendocrine TumorPancreatic Neuroendocrine TumorNETNCT05997056Aadi Bioscience, Inc.12
已完成
2 期
Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed GlioblastomaHigh Grade Recurrent Glioma and Newly Diagnosed GlioblastomaNCT03463265Aadi Bioscience, Inc.62
终止
1 期
Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue SarcomasAdvanced Soft Tissue SarcomaLocally Advanced Soft Tissue SarcomaMetastatic Soft Tissue SarcomaNCT03660930University of Washington19
进行中（未招募）
2 期
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)Tumor, SolidMetastasisMetastatic CancerCancer MetastaticTumorsNeoplasmsNeoplasm MetastasisSolid TumorAdvanced Solid TumorAdvanced CancerMalignant Solid TumorMalignant Solid NeoplasmMalignant NeoplasmMalignant TumorCancerTSC1TSC2Metastatic Solid TumorMetastatic NeoplasmTumorTSCNCT05103358Aadi Bioscience, Inc.120